Inflammation is a physiological process involved in many diseases. Monitoring
proteins involved in regulatory effects may help to improve our understanding of
inflammation. We have analyzed
proteome alterations induced in peripheral blood mononuclear cells (PBMCs) upon inflammatory activation in great detail using high-resolution mass spectrometry. Moreover, the activated cells were treated with
dexamethasone to investigate their response to this antiphlogistic
drug. From a total of 6886 identified
proteins, 469
proteins were significantly regulated upon inflammatory activation. Data are available via ProteomeXchange with identifiers PXD001415-23. Most of these
proteins were counter-regulated by
dexamethasone, with some exceptions concerning members of the
interferon-induced
protein family. To confirm some of these results, we performed targeted MRM analyses of selected
peptides. The
inflammation-induced upregulation of
proteins such as IL-1β,
IL-6, CXCL2, and GROα was confirmed, however, with strong quantitative interindividual differences. Furthermore, the inability of
dexamethasone to downregulate
inflammation-induced
proteins such as PTX3 and TSG6 was clearly demonstrated. In conclusion, the relation of cell function as well as
drug-induced modulation thereof was successfully mapped to
proteomes, suggesting targeted analysis as a novel and powerful
drug evaluation method. Although most consequences of
dexamethasone were found to be compatible with the expected mode of action, some unexpected but significant observations may be related to adverse effects.